Classification of Antiepileptic Drugs
Primary Classification Systems
Antiepileptic drugs are classified into generations based on their development timeline and pharmacological properties, with first-generation agents (phenobarbital, phenytoin, carbamazepine, valproic acid) representing older medications, second-generation agents (felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine, topiramate, vigabatrin, zonisamide) developed between 1989-2009, and third-generation agents (eslicarbazepine acetate, lacosamide) representing the most recent additions. 1, 2
First-Generation Antiepileptics (Traditional/Standard AEDs)
- Phenobarbital - Oldest AED, primarily used in resource-limited settings due to low cost 3
- Phenytoin (Dilantin) - Sodium channel blocker, most frequently prescribed AED in the United States 4
- Carbamazepine - Sodium channel modulator, preferred for partial onset seizures in children and adults 3
- Valproic acid (Depakote) - Broad-spectrum agent effective for multiple seizure types 3
- Ethosuximide - Specifically for typical childhood absence seizures 4
- Primidone - Metabolized to phenobarbital 4
Second-Generation Antiepileptics (1989-2009)
- Felbamate (Felbatol) - Associated with high risk of aplastic anemia and hepatotoxicity; limited use 5, 2
- Gabapentin (Neurontin) - Renally eliminated, no enzyme induction, minimal drug interactions 5, 1
- Lamotrigine (Lamictal) - Sodium channel modulator, effective for partial and generalized seizures, requires slow titration to minimize rash risk 6, 5
- Levetiracetam (Keppra) - Acts on SV2A protein, no significant pharmacokinetic interactions, may cause psychiatric side effects 6, 1
- Oxcarbazepine (Trileptal) - Carbamazepine derivative with better tolerability 5, 2
- Pregabalin - Gabapentin derivative 7, 1
- Tiagabine (Gabitril) - GABA reuptake inhibitor 5, 2
- Topiramate (Topamax) - Multiple mechanisms, effective for partial and generalized seizures 5, 2
- Vigabatrin - GABA transaminase inhibitor, simple pharmacokinetics 5, 1
- Zonisamide (Zonegran) - Broad-spectrum agent 5, 2
Third-Generation Antiepileptics (Post-2009)
- Eslicarbazepine acetate - Carbamazepine derivative with improved profile 7, 1
- Lacosamide - Slow sodium channel inactivation enhancer, minimal drug interactions 3, 1
Alternative Classification by Mechanism of Action
Sodium Channel Blockers
GABA-ergic Agents
Broad-Spectrum Agents
Novel Mechanisms
Classification by Enzyme-Inducing Properties
Enzyme-Inducing AEDs (EIAEDs)
- Phenytoin, phenobarbital, carbamazepine - Induce cytochrome P450 metabolism, cause significant drug interactions including with chemotherapy agents and oral contraceptives 3
Non-Enzyme-Inducing AEDs
- Levetiracetam, lamotrigine, gabapentin, valproic acid, lacosamide - Preferred in patients receiving chemotherapy, targeted therapies, or requiring predictable drug levels 3, 6
Clinical Pitfalls and Key Considerations
Drug Interaction Profile
- Gabapentin, lacosamide, levetiracetam, pregabalin, and vigabatrin have essentially no clinically significant pharmacokinetic interactions 1
- Lamotrigine and topiramate are the most interacting among newer AEDs 1
- Only five newer AEDs (eslicarbazepine, felbamate, oxcarbazepine, rufinamide, topiramate) compromise oral contraceptive efficacy 1
Special Population Considerations
- Women of childbearing age: Avoid valproic acid when possible; use monotherapy at minimum effective dose; supplement with folic acid 3
- Patients with brain tumors: Prefer non-enzyme-inducing AEDs (levetiracetam, lamotrigine) to avoid interactions with chemotherapy and targeted therapies 3, 6
- Intellectual disability with epilepsy: Consider valproic acid or carbamazepine over phenytoin or phenobarbital due to lower risk of behavioral adverse effects 3
Status Epilepticus Treatment Algorithm
- First-line: IV benzodiazepines (lorazepam preferred over diazepam) 3
- Second-line for refractory status: IV phenytoin, fosphenytoin, valproate, or levetiracetam 3
- Third-line: Propofol or barbiturates 3